Boston Scientific has acquired Valencia Technologies in a move to advance its urology and pelvic health portfolio with an implantable tibial nerve stimulation (ITNS) treatment.
California-based Valencia’s lead product is eCoin, an ITNS system for urge urinary incontinence (UUI) treatment. Implanted under the skin near the ankle, the coin-sized device is intended for patients who are intolerant to or have responded inadequately to more conservative UUI treatments.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
UUI is a common symptom of overactive bladder (OAB). Research indicates that almost 30 million US adults aged 40 and above display symptoms of OAB.
Gaining US Food and Drug Administration (FDA) clearance in 2022, eCoin addresses UUI by stimulating the tibial nerve to regulate how the brain communicates with the bladder. In the system’s pivotal trial (NCT03556891), 68% of patients responded with a reduction of at least 50% in UUI episodes.
The transaction, the terms of which have not been publicly disclosed, is expected to complete in the first half of 2026.
Once the deal closes, Boston will be in market contention with Medtronic’s Altaviva device for UUI treatment. Altaviva gained US Food and Drug Administration (FDA) clearance in September 2025. At the ongoing J.P. Morgan Healthcare conference, Medronic CEO Jeff Martha revealed that over 500 physicians have been trained to use Altaviva since its approval, thereby reflecting the strong interest levels in the device.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataBoston’s acquisition of Valencia represents the company’s latest move to bolster its urology portfolio with a neuromodulation treatment. In 2024, Boston acquired Axonics in a deal worth around $3.3bn that added a sacral neuromodulation (SNM) therapy for OAB and faecal incontinence treatment to Boston’s urology portfolio.
Meghan Scanlon, senior vice president and president of urology at Boston Scientific said the addition of the eCoin system will expand the company’s product portfolio into ITNS, an area it views as a “high-growth adjacency” to Boston’s urology business.
Scanlon continued: “ITNS technology complements our existing pelvic health product line, and we look forward to offering a more comprehensive set of treatment options to patients across the care continuum.”
In Boston’s most recent financial report, its urology segment achieved revenue of $682m, reflecting a Q3 2025 uplift of over 28% versus the same period in 2024.
Boston’s acquisition of Valencia reflects the latest move to advance its broader neurological device portfolio. In October 2025, Boston acquired Nalu Medical in a deal worth around $533m. Nalu’s lead product is a neurostimulation system that is designed to address chronic pain in regions such as the shoulder, lower back and knee via peripheral nerve stimulation (PNS).
According to GlobalData analysis, the global neurology devices market is projected to reach a valuation above $25bn in 2034.
